Vireo Growth (VREOF) Revenue Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Revenue Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.83 Bn | 32.09 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 2.94% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 77.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.20% |
| Dec 31, 2025 | 76.39% |
| Sep 30, 2025 | 69.40% |
| Jun 30, 2025 | 31.60% |
| Mar 31, 2025 | 16.14% |
| Dec 31, 2024 | 22.37% |
| Sep 30, 2024 | 23.47% |
| Jun 30, 2024 | 20.84% |
| Mar 31, 2024 | 22.23% |
| Dec 31, 2023 | 24.92% |
| Sep 30, 2023 | 25.53% |
| Jun 30, 2023 | 18.25% |
| Mar 31, 2023 | 16.35% |